Literature DB >> 16514202

Role of the N, N'-dimethylbiguanide metformin in the treatment of female prepuberal BALB/c mice hyperandrogenized with dehydroepiandrosterone.

Valeria Sander1, Carolina Griselda Luchetti, María Emilia Solano, Evelin Elia, Guillermo Di Girolamo, Claudio Gonzalez, Alicia Beatriz Motta.   

Abstract

The present study investigated the role of the N, N{'}-dimethylbiguanide metformin (50 mg/100 g body weight in 0.05 ml water, given orally with a canulla) in the prevention of endocrine and immune disorders provoked by the hyperandrogenization with dehydroepiandrosterone (DHEA) in prepuberal BALB/c mice. The treatment with DHEA (6 mg/100 g body weight in 0.1 ml oil) for 20 consecutive days, recreates a mouse model that resembles some aspects of the human polycystic ovary syndrome (PCOS). The treatment with DHEA did not modify either body mass index (BMI) or blood glucose levels, but did increase fasting insulin levels when compared with controls. Markers of ovarian function - serum estradiol (E), progesterone (P) and ovarian prostaglandin E (PGE) - were evaluated. The treatment with DHEA increased serum E and P levels while ovarian PGE diminished. When metformin was administered together with DHEA, serum insulin, E and P levels, and ovarian PGE values did not differ when compared with controls. Using flow cytometry assays we found that the treatment with DHEA diminished the percentage of the CD4 + T lymphocyte population and increased the percentage of the CD8 + T lymphocyte population from both ovarian tissue and retroperitoneal lymph nodes. However, when metformin was administered together with DHEA, the percentages of CD4 + and CD8 + T lymphocyte populations from both ovarian tissue and retroperitoneal lymph nodes were similar to those observed in controls. Finally, when DHEA was administered alone it increased the serum tumor necrosis factor-alpha (TNF-alpha ) levels when compared with controls; however, when metformin was administered together with DHEA, serum TNF-alpha levels were similar to controls. These results indicate that metformin is able, directly or indirectly, to avoid the endocrine and immune alterations produced when mice are hyperandrogenized with DHEA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16514202     DOI: 10.1530/rep.1.00941

Source DB:  PubMed          Journal:  Reproduction        ISSN: 1470-1626            Impact factor:   3.906


  19 in total

1.  High levels of testosterone inhibit ovarian follicle development by repressing the FSH signaling pathway.

Authors:  Tao Liu; Yu-Qian Cui; Han Zhao; Hong-Bin Liu; Shi-Dou Zhao; Yuan Gao; Xiao-Li Mu; Fei Gao; Zi-Jiang Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-10-22

2.  Hyperandrogenemia Induced by Letrozole Treatment of Pubertal Female Mice Results in Hyperinsulinemia Prior to Weight Gain and Insulin Resistance.

Authors:  Danalea V Skarra; Angelina Hernández-Carretero; Alissa J Rivera; Arya R Anvar; Varykina G Thackray
Journal:  Endocrinology       Date:  2017-09-01       Impact factor: 4.736

Review 3.  Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis.

Authors:  Héctor F Escobar-Morreale; Manuel Luque-Ramírez; Frank González
Journal:  Fertil Steril       Date:  2010-12-17       Impact factor: 7.329

4.  Rhamnocitrin Attenuates Ovarian Fibrosis in Rats with Letrozole-Induced Experimental Polycystic Ovary Syndrome.

Authors:  Yanyuan Zhou; Huan Lan; Zhewen Dong; Wanying Li; Bo Qian; Zhen Zeng; Wen He; Jia-Le Song
Journal:  Oxid Med Cell Longev       Date:  2022-05-26       Impact factor: 7.310

5.  Dehydroepiandrosterone and metformin regulate proliferation of murine T lymphocytes.

Authors:  M E Solano; V Sander; M R Wald; A B Motta
Journal:  Clin Exp Immunol       Date:  2008-06-28       Impact factor: 4.330

Review 6.  The role of androgens in follicle maturation and ovulation induction: friend or foe of infertility treatment?

Authors:  Norbert Gleicher; Andrea Weghofer; David H Barad
Journal:  Reprod Biol Endocrinol       Date:  2011-08-17       Impact factor: 5.211

7.  Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome.

Authors:  Irene Tessaro; Silvia C Modina; Federica Franciosi; Giulia Sivelli; Laura Terzaghi; Valentina Lodde; Alberto M Luciano
Journal:  J Ovarian Res       Date:  2015-10-06       Impact factor: 4.234

8.  Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer.

Authors:  Di Wu; Di Hu; Hao Chen; Guoming Shi; Irfete S Fetahu; Feizhen Wu; Kimberlie Rabidou; Rui Fang; Li Tan; Shuyun Xu; Hang Liu; Christian Argueta; Lei Zhang; Fei Mao; Guoquan Yan; Jiajia Chen; Zhaoru Dong; Ruitu Lv; Yufei Xu; Mei Wang; Yong Ye; Shike Zhang; Danielle Duquette; Songmei Geng; Clark Yin; Christine Guo Lian; George F Murphy; Gail K Adler; Rajesh Garg; Lydia Lynch; Pengyuan Yang; Yiming Li; Fei Lan; Jia Fan; Yang Shi; Yujiang Geno Shi
Journal:  Nature       Date:  2018-07-18       Impact factor: 49.962

9.  The mechanism of mTOR (mammalian target of rapamycin) in a mouse model of polycystic ovary syndrome (PCOS).

Authors:  Aylin Yaba; Necdet Demir
Journal:  J Ovarian Res       Date:  2012-11-27       Impact factor: 4.234

10.  Oriental medicine Kyung-Ok-Ko prevents and alleviates dehydroepiandrosterone-induced polycystic ovarian syndrome in rats.

Authors:  Minhee Jang; Min Jung Lee; Jin Moo Lee; Chun-Sik Bae; Sung-Hoon Kim; Jong Hoon Ryu; Ik-Hyun Cho
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.